Analysts expect AzurRx BioPharma Inc (NASDAQ:AZRX) to post earnings of ($0.17) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for AzurRx BioPharma’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.20). AzurRx BioPharma posted earnings of ($0.24) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 29.2%. The business is expected to report its next quarterly earnings report on Monday, April 6th.

According to Zacks, analysts expect that AzurRx BioPharma will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.82) to ($0.69). For the next financial year, analysts forecast that the company will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.72) to ($0.41). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow AzurRx BioPharma.

A number of brokerages have recently commented on AZRX. HC Wainwright set a $5.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday, October 18th. Maxim Group set a $3.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 15th. Six equities research analysts have rated the stock with a buy rating, AzurRx BioPharma currently has an average rating of “Buy” and an average target price of $7.10.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in AzurRx BioPharma during the 3rd quarter valued at $51,000. Royal Bank of Canada purchased a new position in AzurRx BioPharma during the 2nd quarter valued at $48,000. Vanguard Group Inc. boosted its holdings in AzurRx BioPharma by 255.0% during the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock valued at $443,000 after acquiring an additional 186,985 shares during the period. BlackRock Inc. boosted its holdings in AzurRx BioPharma by 57.6% during the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock valued at $72,000 after acquiring an additional 15,463 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in AzurRx BioPharma during the 2nd quarter valued at $57,000. Institutional investors own 9.52% of the company’s stock.

Shares of AzurRx BioPharma stock traded up $0.01 on Wednesday, reaching $0.75. The company had a trading volume of 133,649 shares, compared to its average volume of 195,218. The firm has a market cap of $19.70 million, a price-to-earnings ratio of -0.86 and a beta of 2.12. The firm’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $1.15. AzurRx BioPharma has a 1 year low of $0.42 and a 1 year high of $3.10.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: How is a management fee different from a performance fee?

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.